SG11202105422RA - Hsv vector with reduced neurotoxicity - Google Patents

Hsv vector with reduced neurotoxicity

Info

Publication number
SG11202105422RA
SG11202105422RA SG11202105422RA SG11202105422RA SG11202105422RA SG 11202105422R A SG11202105422R A SG 11202105422RA SG 11202105422R A SG11202105422R A SG 11202105422RA SG 11202105422R A SG11202105422R A SG 11202105422RA SG 11202105422R A SG11202105422R A SG 11202105422RA
Authority
SG
Singapore
Prior art keywords
hsv vector
reduced neurotoxicity
neurotoxicity
reduced
hsv
Prior art date
Application number
SG11202105422RA
Inventor
William Jia
Dmitry Chouljenko
I-Fang Lee
Yanal Murad
Xiaohu Liu
Guoyu Liu
Xuexian Bu
Zahid Delwar
Original Assignee
Virogin Biotech Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogin Biotech Canada Ltd filed Critical Virogin Biotech Canada Ltd
Publication of SG11202105422RA publication Critical patent/SG11202105422RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
SG11202105422RA 2018-11-29 2019-11-29 Hsv vector with reduced neurotoxicity SG11202105422RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773119P 2018-11-29 2018-11-29
PCT/US2019/063838 WO2020113151A1 (en) 2018-11-29 2019-11-29 Hsv vector with reduced neurotoxicity

Publications (1)

Publication Number Publication Date
SG11202105422RA true SG11202105422RA (en) 2021-06-29

Family

ID=70849003

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105422RA SG11202105422RA (en) 2018-11-29 2019-11-29 Hsv vector with reduced neurotoxicity

Country Status (9)

Country Link
US (1) US20200171110A1 (en)
EP (1) EP3886860A4 (en)
JP (1) JP2022513639A (en)
KR (1) KR20210098483A (en)
CN (1) CN113164484A (en)
AU (1) AU2019389108A1 (en)
CA (1) CA3119801A1 (en)
SG (1) SG11202105422RA (en)
WO (1) WO2020113151A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220305066A1 (en) 2020-06-12 2022-09-29 Gencellmed Inc. Recombinant herpes simplex virus for multiple targeting and use thereof
CA3203135A1 (en) * 2020-12-04 2022-06-09 Immvira Co., Limited Oncolytic herpes simplex type 1 viruses for treatment of brain tumors
EP4313094A1 (en) * 2021-03-24 2024-02-07 Virogin Biotech Canada Ltd Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors
CN114010666A (en) * 2021-10-22 2022-02-08 上海交通大学 Application of oncolytic virus, PARP inhibitor and PD-1 antibody in preparation of antitumor drugs
WO2023081348A1 (en) * 2021-11-04 2023-05-11 Mayo Foundation For Medical Education And Research Herpesviral combination therapy for targeting cancer cells and cancer associated stromal cells
WO2023147566A1 (en) * 2022-01-29 2023-08-03 Virogin Biotech Canada Ltd Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors
WO2023142040A1 (en) * 2022-01-29 2023-08-03 Virogin Biotech Canada Ltd. Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2173378B1 (en) * 2007-06-27 2014-03-19 Admune Therapeutics LLC Complexes of il-15 and il-15ralpha and uses thereof
RU2573912C2 (en) * 2008-10-08 2016-01-27 Интрексон Корпорейшн Constructed cells, expressing multiple immunomodulators, and thereof application
US20140363469A1 (en) * 2012-01-19 2014-12-11 Alnylam Pharmaceuticals, Inc. Viral attenuation and vaccine production
CA2988196C (en) * 2015-05-04 2021-04-27 The Brigham And Women's Hospital, Inc. Oncolytic hsv1 vector and methods of use
GB201520345D0 (en) * 2015-11-18 2015-12-30 Virttu Biolog Ltd Herpes simplex viruses
JP2019508063A (en) * 2016-01-27 2019-03-28 オンコラス， インコーポレイテッド Oncolytic virus vector and use thereof
WO2018026872A1 (en) * 2016-08-01 2018-02-08 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
CN111212656A (en) * 2017-07-26 2020-05-29 昂克诺斯公司 Oncolytic viral vectors and uses thereof
CN111712250A (en) * 2017-11-16 2020-09-25 复诺健生物科技加拿大有限公司 Targeting moiety modified oncolytic viruses
US20210046130A1 (en) * 2018-01-24 2021-02-18 Virogin Biotech Canada Ltd Recombinant viral vaccines
EP3781188A4 (en) * 2018-04-13 2022-03-02 2seventy bio, Inc. Adoptive cellular therapy

Also Published As

Publication number Publication date
CA3119801A1 (en) 2020-06-04
EP3886860A1 (en) 2021-10-06
US20200171110A1 (en) 2020-06-04
KR20210098483A (en) 2021-08-10
JP2022513639A (en) 2022-02-09
CN113164484A (en) 2021-07-23
WO2020113151A1 (en) 2020-06-04
EP3886860A4 (en) 2022-08-03
AU2019389108A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
GB2560400B (en) Vector processing unit
HK1259157A1 (en) Vector reduction processor
SG11202105422RA (en) Hsv vector with reduced neurotoxicity
GB2549809C (en) Vector
SG11201913142XA (en) Ship
PT3432912T (en) High-transducing hsv vectors
GB201614093D0 (en) Vector
SG11202001767YA (en) Ship
GB201715052D0 (en) Vectors
GB202016862D0 (en) Vector
GB201717524D0 (en) Vectors
GB201807945D0 (en) Vector production
IL274178A (en) Vector add-with-carry instruction
SG11202001976VA (en) Ship
EP3714724C0 (en) Dock type slider
GB201913974D0 (en) Vector
IL274278A (en) Vectors
SG11202003462SA (en) Prenylation assay
GB201718294D0 (en) Vector construct
IL261309B (en) Processing vector instructions
IL261895B (en) Middle point zero reference
GB201705927D0 (en) Vector
GB201914984D0 (en) Vector
GB201906283D0 (en) Vector
EP3676717A4 (en) Transcoding with a vector processing unit